ESR1 and breast cancer: Mutations in ERα and loss of ERα expression can also lead to therapy resistance, however these changes are far less common with only around 15–20% of resistant BC losing ERα expression [14] and only 1% of BC exhibiting mutations in ESR1, suggesting that more complex signalling mechanisms are the predominant factor in hormone therapy resistance [17] (Figure 1).